Top Industry Leaders in the Cancer API Market
Latest Cancer API Companies Updates:
Biocon Biopharma Ltd. partners with Merck KGaA for an undisclosed multi-year deal: This collaboration announced in October 2023 focuses on developing and manufacturing high-value APIs for oncology drugs.
WuXi AppTec acquires Alvotech Holdings for around $3.3 billion: This acquisition in December 2023 bolsters WuXi's API manufacturing capabilities and expands its oncology portfolio.
Samsung Biologics announces a $300 million investment to expand its API manufacturing capacity: This move in September 2023 aims to meet the growing demand for oncology APIs.
Lonza invests $80 million in its Visp, Switzerland site to expand its API production capacity for highly potent active pharmaceutical ingredients (HPAPIs): This commitment emphasizes the focus on complex APIs for cancer drugs.
Novavax secures FDA approval for its protein-based COVID-19 vaccine, Nuvaxovid: This approval in July 2023 opens doors for future development of similar cancer vaccines.
AstraZeneca announces positive Phase III results for its ADC (Antibody-Drug Conjugate) therapy for lung cancer: This breakthrough in December 2023 could lead to a new targeted treatment option.
List of Cancer API Key companies in the market:
- Reddy’s Laboratories Ltd
- Sun Pharmaceuticals Industries Ltd
- Beta Drugs Limited
- Axplora
- Bulat Pharmaceutical
- Avra Laboratories Pvt Ltd
- Biocon
- Teva Pharmaceutical Industries Ltd
- Bochem Pvt. Ltd
- Mac-Chem Products (India) Pvt. Ltd